Current pediatrics reports最新文献

{"title":"Recent Advances in Acute Kidney Injury in Preterm Infants","authors":"B. Massa-Buck, S. Rastogi","doi":"10.1007/s40124-022-00271-2","DOIUrl":"https://doi.org/10.1007/s40124-022-00271-2","url":null,"abstract":"","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"165 - 171"},"PeriodicalIF":0.0,"publicationDate":"2022-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46320586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the Future of Patients with Obstructive Uropathy—A Comprehensive Review","authors":"J. Richter, M. Rickard, J. Kim, L. Erdman, A. Lorenzo, M. Chua","doi":"10.1007/s40124-022-00272-1","DOIUrl":"https://doi.org/10.1007/s40124-022-00272-1","url":null,"abstract":"","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"202 - 213"},"PeriodicalIF":0.0,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48999218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric to Adult Transition for Adolescents and Young Adults with Kidney Transplant","authors":"Ashley A. Sharma, Amita Sharma","doi":"10.1007/s40124-022-00266-z","DOIUrl":"https://doi.org/10.1007/s40124-022-00266-z","url":null,"abstract":"","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"155-163"},"PeriodicalIF":0.0,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42330855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Climate Change and Its Effects on Children and Adolescents: a Call to Action","authors":"M. Goldstein","doi":"10.1007/s40124-022-00263-2","DOIUrl":"https://doi.org/10.1007/s40124-022-00263-2","url":null,"abstract":"","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"55-56"},"PeriodicalIF":0.0,"publicationDate":"2022-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46828860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trauma-Informed Care for Hospitalized Adolescents","authors":"A. Fialkowski, Katherine Shaffer, Maya Ball-Burack, Traci L Brooks, Nhi-Ha T. Trinh, J. Potter, Katherine R. Peeler","doi":"10.1007/s40124-022-00262-3","DOIUrl":"https://doi.org/10.1007/s40124-022-00262-3","url":null,"abstract":"","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"45 - 54"},"PeriodicalIF":0.0,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47626209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine Hesitancy: Obstacles and Challenges.","authors":"Preeti M Galagali,&nbsp;Aarti Avinash Kinikar,&nbsp;Vikram Sakaleshpur Kumar","doi":"10.1007/s40124-022-00278-9","DOIUrl":"https://doi.org/10.1007/s40124-022-00278-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>In 2019, vaccine hesitancy (VH) was named as one of the top 10 threats to global health by the World Health Organization (WHO). We highlight the factors affecting VH, the role of VH in limiting vaccine uptake and inability to achieve collective immunity, and possible solutions.</p><p><strong>Recent findings: </strong>There are still uncertainties and concerns about the safety and efficacy of vaccines, which promote VH and undermine public confidence in immunization. WHO has designed the behavioral and social drivers (BeSD) tools and survey instruments that can be used by countries to assess reasons for poor vaccine uptake in childhood for COVID-19 and plan national vaccination programs to counter these misconceptions.</p><p><strong>Summary: </strong>Vaccines are one of the best preventative measures that public health care has to offer. Evidence from across the world both in high-income countries (HICs) and low/middle-income countries (LMICs) show that VH is a significant phenomenon which is translating into geographical clustering of epidemics. A reasonably high acceptance and coverage rates are necessary for an immunization program to be successful. A context-specific and multifactorial intervention with more high-quality research is needed globally.</p>","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 4","pages":"241-248"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33542003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of MIS-C in Children and Adolescents.","authors":"Sanaa Mahmoud, Mostafa El-Kalliny, Alyaa Kotby, Mona El-Ganzoury, Eman Fouda, Hanan Ibrahim","doi":"10.1007/s40124-021-00259-4","DOIUrl":"10.1007/s40124-021-00259-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Different treatment approaches have been described for the management of COVID-19-related multisystem inflammatory syndrome in children (MIS-C), the pathogenesis of which has not yet been fully elucidated. Here, we comprehensively review and summarize the recommendations and management strategies that have been published to date.</p><p><strong>Recent findings: </strong>MIS-C patients are treated with different regimens, mostly revolving around the use of immunomodulatory medications, including IVIG and glucocorticoids as first-tier therapy. Refractoriness to IVIG and glucocorticoids warrants a step-up of immunomodulatory therapy to biologic agents such as anakinra, tocilizumab, and infliximab.</p><p><strong>Summary: </strong>We review the current evidence regarding the use of monotherapy versus combination therapy, as well as the current recommendations for assessing thrombotic risk and administering antiplatelet and anticoagulant therapy. We anticipate that future studies will provide evidence for management plans that maximize short- and long-term outcomes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40124-021-00259-4.</p>","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"1-10"},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39827373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Complications of COVID-19 Infection in Adolescents and Children.","authors":"Keerthi Thallapureddy, Khyathi Thallapureddy, Erika Zerda, Neeraj Suresh, Deepak Kamat, Karthik Rajasekaran, Alvaro Moreira","doi":"10.1007/s40124-021-00260-x","DOIUrl":"10.1007/s40124-021-00260-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Compared to adults, post-COVID-19 symptoms are uncommon and have not been thoroughly evaluated in children. This review summarizes the literature in terms of persistent symptoms in children and adolescents after SARS-CoV-2 infection.</p><p><strong>Recent findings: </strong>Children were less likely to develop long COVID when compared to adults. Older children (e.g., adolescents) and those who had symptomatic COVID-19 had a higher probability for long COVID.</p><p><strong>Summary: </strong>Families and health care providers need to be aware of a new constellation of long COVID symptoms in the pediatric population. More evidence and time are needed to better understand the potential effects of long COVID-19 in children and adolescents. In comparison to adults, children are less likely to have persistent COVID-19 symptoms.</p>","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"11-17"},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39894411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents-a Live Systematic Review and Meta-analysis.","authors":"Li Jiang, Kun Tang, Omar Irfan, Xuan Li, Enyao Zhang, Zulfiqar Bhutta","doi":"10.1007/s40124-022-00264-1","DOIUrl":"10.1007/s40124-022-00264-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>A multisystem inflammatory condition occurring in children and adolescents with COVID-19 has become increasingly recognized and widely studied globally. This review aims to investigate and synthesize evolving evidence on its clinical characteristics, management, and outcomes in pediatric patients.</p><p><strong>Recent findings: </strong>We retrieved data from PubMed, EMBASE, Cochrane Library, WHO COVID-19 Database, Google Scholar, and preprint databases, covering a timeline from December 1, 2019, to July 31, 2021. A total of 123 eligible studies were included in the final descriptive and risk factor analyses. We comprehensively reviewed reported multisystem inflammatory syndrome in children (MIS-C) cases from published and preprint studies of various designs to provide an updated evidence on epidemiology, clinical, laboratory and imaging findings, management, and short-term outcomes. Latest evidence suggests that African black and non-Hispanic white are the two most common ethnic groups, constituting 24.89% (95% CI 23.30-26.48%) and 25.18% (95% CI 23.51-26.85%) of the MIS-C population, respectively. Typical symptoms of MIS-C include fever (90.85%, 95% CI 89.86-91.84%), not-specified gastrointestinal symptoms (51.98%, 95% CI 50.13-53.83%), rash (49.63%, 95% CI 47.80-51.47%), abdominal pain (48.97%, 95% CI 47.09-50.85%), conjunctivitis (46.93%, 95% CI 45.17-48.69%), vomiting (43.79%, 95% CI 41.90-45.68%), respiratory symptoms (41.75%, 95% CI 40.01-43.49%), and diarrhea (40.10%, 95% CI 38.23-41.97%). MIS-C patients are less likely to develop conjunctivitis (OR 0.27, 95% CI 0.11-0.67), cervical adenopathy (OR 0.21, 95% CI 0.07-0.68), and rash (OR 0.44, 95% CI 0.26-0.77), in comparison with Kawasaki disease patients. Our review revealed that the majority of MIS-C cases (95.21%) to be full recovered while only 2.41% died from this syndrome. We found significant disparity between low- and middle-income countries and high-income countries in terms of clinical outcomes.</p><p><strong>Summary: </strong>MIS-C, which appears to be linked to COVID-19, may cause severe inflammation in organs and tissues. Although there is emerging new evidence about the characteristics of this syndrome, its risk factors, and clinical prognosis, much remains unknown about the causality, the optimal prevention and treatment interventions, and long-term outcomes of the MIS-C patients.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40124-022-00264-1.</p>","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"19-30"},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48989900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term COVID 19 Sequelae in Adolescents: the Overlap with Orthostatic Intolerance and ME/CFS.","authors":"Amanda K Morrow, Laura A Malone, Christina Kokorelis, Lindsay S Petracek, Ella F Eastin, Katie L Lobner, Luise Neuendorff, Peter C Rowe","doi":"10.1007/s40124-022-00261-4","DOIUrl":"10.1007/s40124-022-00261-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>To discuss emerging understandings of adolescent long COVID or post-COVID-19 conditions, including proposed clinical definitions, common symptoms, epidemiology, overlaps with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and orthostatic intolerance, and preliminary guidance on management.</p><p><strong>Recent findings: </strong>The recent World Health Organization clinical case definition of post-COVID-19 condition requires a history of probable or confirmed SARS-CoV-2 infection, with symptoms starting within 3 months of the onset of COVID-19. Symptoms must last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms of the post-COVID-19 condition include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction. These symptoms generally have an impact on everyday functioning. The incidence of prolonged symptoms following SARS-CoV-2 infection has proven challenging to define, but it is now clear that those with relatively mild initial infections, without severe initial respiratory disease or end-organ injury, can still develop chronic impairments, with symptoms that overlap with conditions like ME/CFS (profound fatigue, unrefreshing sleep, post-exertional malaise, cognitive dysfunction, and orthostatic intolerance).</p><p><strong>Summary: </strong>We do not yet have a clear understanding of the mechanisms by which individuals develop post-COVID-19 conditions. There may be several distinct types of long COVID that require different treatments. At this point, there is no single pharmacologic agent to effectively treat all symptoms. Because some presentations of post-COVID-19 conditions mimic disorders such as ME/CFS, treatment guidelines for this and related conditions can be helpful for managing post-COVID-19 symptoms.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40124-022-00261-4.</p>","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":"10 1","pages":"31-44"},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45575688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}